Skip to content

Effectiveness of Transaural Vagus Nerve Stimulation for the Treatment of Globus Pharyngeus: A Prospective Single-Center Study

Effectiveness of Transaural Vagus Nerve Stimulation for the Treatment of Globus Pharyngeus: A Prospective Single-Center Study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091321
Enrollment
Unknown
Registered
2024-10-25
Start date
2024-03-04
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Globus Pharyngeus

Interventions

Single group:Transcutaneous auricular vagus nerve stimulation

Sponsors

Wuxi Huishan District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged between 18 and 75 years; 2.Patients diagnosed with Globus Pharyngeus (GP) based on clinical symptoms and necessary examinations; 3.A score of 6 or higher on the Laryngopharyngeal Measure of Perceived Sensation (LUMP); 4.Patients willing to undergo transaural vagus nerve stimulation (taVNS) treatment and capable of adhering to the study protocol and requirements; 5.Patients who have fully understood the study details and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Presence of other serious medical conditions that may affect study outcomes or patient safety, such as severe cardiac disease, psychiatric disorders, or neurological diseases; 2.Patients with implanted medical devices, including pacemakers, neural stimulators, or other electronic medical devices; 3.Ear diseases: Individuals suffering from conditions such as otitis media or external otitis, which may interfere with the administration of taVNS treatment; 4.Medication use: Patients currently undergoing pharmacological treatments that could affect the symptoms of Globus Pharyngeus (GP), who are unwilling to pause these medications during the study period; 5.Pregnancy or breastfeeding: Women who are currently pregnant or breastfeeding; 6.Recent participation in other clinical trials: Patients who have participated in another clinical trial within the past three months; 7.Language or cognitive impairments: Patients with language comprehension or cognitive impairments that prevent them from understanding study requirements or independently completing questionnaires; 8.History of allergies or adverse reactions to electrical stimulation.

Design outcomes

Primary

MeasureTime frame
Laryngopharyngeal Measure of Perceived Sensation (LUMP) ;

Secondary

MeasureTime frame
SAS;SDS;

Countries

China

Contacts

Public ContactMeng Xiangming

Wuxi Huishan District People’s Hospital

xiangming_meng@hotmail.com+86 180 1839 0579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026